A review of pretreatment and analytical methods for H2 receptor antagonists: An update since 2019.

Ultrasound-assisted emulsification microextraction and dispersive liquid-liquid microextraction were compared for extraction of ephedrine, norephedrine, and pseudoephedrine from human urine samples prior to their determination by capillary electrophoresis. Formation of a microemulsion of the organic extract with an aqueous solution (at pH 3.2) containing 10% methanol facilitated the direct injection of the final extract into the capillary. Influential parameters affecting extraction efficiency were systematically studied and optimized. In order to enhance the sensitivity further, field-amplified sample injection was applied. Under optimum extraction and stacking conditions, enrichment factors of up to 140 and 1750 as compared to conventional capillary zone electrophoresis were obtained resulting in limits of detection of 12-33 μg/L and 1.0-2.8 μg/L with dispersive liquid-liquid microextraction and ultrasound-assisted emulsification microextraction when combined with field-amplified sample injection. Calibration graphs showed good linearity for urine samples by both methods with coefficients of determination higher than 0.9973 and percent relative standard deviations of the analyses in the range of 3.4-8.2% for (n = 5). The results showed that the use of ultrasound to assist microextraction provided higher extraction efficiencies than disperser solvents, regarding the hydrophilic nature of the investigated analytes.

Aspirin has an anti-platelet effect, and is being widely used for the prevention and treatment of thrombosis. Despite the benefits of aspirin in preventing thrombus, however, gastrointestinal complications often occur as an adverse effect and though many studies on the gastrointestinal complications due to high-dose aspirin have been conducted, there have been few studies on gastrointestinal complications due to low-dose aspirin. This paper describes the results of research on gastrointestinal complications due to low-dose aspirin conducted at a health insurance pharmacy.The prescribing frequencies of low-dose aspirin, antisecretory drugs (H2 receptor antagonists and proton pump inhibitors) at the health insurance pharmacy were calculated and then the prescription data was further classified according to concomitant use of low-dose aspirin products with antisecretory drugs, and the odds ratio of concomitant use was estimated. During the period from April, 2003 to March, 2004 the odds ratio of concomitant use of aspirin with antisecretory drugs was 2.07 (95% CI, 1.03-4.14).In this study, no patient was found to be taking antisecretory drugs concomitantly with aspirin and thus antisecretory drugs were not being used to prevent the gastrointestinal complications of aspirin. Our findings suggest that the risk of the gastrointestinal complications could be increased by taking low-dose aspirin over the long term.

We investigated the risk of upper gastrointestinal (UGI) bleeding and the protective effect of concomitant anti-secretory drugs during dual antiplatelet therapy administered following implantation of drug-eluting stents (DES) for coronary heart disease. Because proton pump inhibitors (PPIs) are reported to decrease the platelet inhibitory effects of clopidogrel, we also assessed cardiovascular outcomes in patients taking thienopyridine derivatives with or without anti-secretory drug. We retrospectively analyzed 243 patients, who underwent DES implantation between January 2006 and December 2007 and were receiving dual anti-platelet therapy post-surgery. The main outcome measurement was the presence of UGI bleeding. Cardiovascular outcomes were assessed by follow-up coronary angiography (CAG) findings. Data were collected from medical records. Eight cases of UGI bleeding were observed during the follow-up period, none of whom were taking anti-secretory drugs. Among the 243 cases, 108 cases were taking anti-secretory drugs: a PPI (67 cases), and an H2 receptor antagonist (41 cases). No UGI bleeding was observed among patients who were taking concomitant anti-secretory drugs. The 1- and 2-year cumulative incidences of UGI bleeding among patients who were not taking anti-secretory drugs were 4.5% and 9.2%, respectively. When CAG findings were compared between patients not taking any anti-secretory drug, taking PPI, or taking H2RA, significantly more stenotic lesions of the coronary artery were observed in the PPI-treatment group. Concomitant use of an anti-secretory agent was associated with a reduced risk of UGI bleeding. Use of PPI may be associated with an attenuation of the effect of dual antiplatelet therapy.

There is no clear evidence yet on the best treatment for functional dyspepsia. A variety of drugs are used to try and relieve dyspepsia. Antisecretory drugs are one of the mainstays of treatment. In a Cochrane meta-analysis of randomized trials, antisecretory drugs (H2 receptor antagonists and proton pump inhibitors) were found to be more effective than placebos, and there were no differences between H2 receptor antagonists and proton pump inhibitors. The effectiveness is independent of the subtype, dose, duration of treatment, and Helicobacter pylori status in both drugs. The effect of Helicobacter pylori eradication therapy, on the symptoms of functional dyspepsia, is modest. The effect of H2 receptor antagonists and proton pump inhibitors therapy on functional dyspepsia may be overestimated because most existing trials were performed utilizing the Rome I and II classification of functional dyspepsia.

Simultaneous determination of cork taint and Brett character responsible compounds in wine using ultrasound-assisted emulsification microextraction with solidification of floating organic drop

Development of liquid phase microextraction based on manual shaking and ultrasound-assisted emulsification method for analysis of organochlorine pesticides in aqueous samples

Sweeteners in food samples: An update on pretreatment and analysis techniques since 2015

Simple Approach Based On Ultrasound-Assisted Emulsification Microextraction For Determination Of β-Sitosterol In Dietary Supplements And Selected Food Products

A rapid, sensitive, and accurate analytical method was developed for determination of lactic acid (LA) in human plasma to monitor lactic acidosis. This method was based on an ultrasound-assisted emulsification microextraction (USAEME) method followed by gas chromatography with flame ionization detection (GC–FID). Derivatization of LA was carried out by a low density alcoholic solvent which performs both as an extraction solvent and derivatization agent, simultaneously. In this procedure, 100 μL of binary mixtures of pentan-1-ol with toluene (70 : 30, v/v %) was slowly injected into a 10 mL acidified aqueous sample of LA placed into an ultrasonic water bath. The resulting emulsion was centrifuged and after derivatization, 2 μL of organic phase was analysed by GC–FID. The effective variables were evaluated to optimize the efficiency of USAEME. Under the optimum conditions, good linearity in the range of 0.06–7.77 mmol L–1 was obtained with a correlation coefficient (R2) of 0.991 and a limit of detection (LOD) of 0.04 mmol L–1 for water samples. The inter-day and intra-day repeatability of the proposed method in human plasma were evaluated in terms of the relative standard deviation (RSD %) and were found to be <10 %. The results revealed that the USAEME–GC–FID method can be applied successfully for determination of LA in human plasma samples with satisfactory accuracy and precision.

Heartburn affects 25% of the adult population on a monthly basis and represents the core symptom of gastro-oesophageal reflux disease (GORD). Treatment is readily available and puts a large demand on healthcare budgets. Research in the past has focused largely on the treatment of oesophagitis. A majority of GORD patients show no endoscopic abnormalities and in daily practice most patients are treated empirically. Summarise, quantify and compare the efficacy of the short-term use of proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and prokinetics in the empirical treatment of GORD and the treatment of endoscopy negative reflux disease (ENRD). Electronic searches were performed of the Cochrane Controlled Trials Register, MEDLINE and EMBASE. Bibliographies were screened. Included were randomised controlled trials focussing on symptomatic outcome after short-term treatment for GORD using proton pump inhibitors, H2-receptor antagonists or prokinetic agents. Participants had to be classifiable in the empirical treatment group (no endoscopy used in treatment allocation) or in the endoscopy negative reflux disease group (no endoscopic signs of erosive oesophagitis). Data from included trials were extracted by two reviewers independently. The impact of interventions was expressed as relative risks (RR) together with 95% confidence intervals (95% CI). Meta-analysis was only performed if there were sufficient trials of similar comparisons reporting the same outcomes. Relative risks were combined for binary outcomes. Twenty-one trials were included: eleven in the empirical treatment group, seven in the ENRD group and three in both. In empirical treatment of GORD the RR for heartburn remission in placebo-controlled trials for PPI was 0.35 (1 trial, 95% CI 0.26 to 0.46), for H2RAs 0.77 (2 trials, 95% CI 0.60 to 0.99) and for prokinetics 0.86 (1 trial, 95% CI 0.73 to 1.01). In direct comparison PPIs were significantly (p<0.05) more effective than H2RAs (3 trials, RR 0.67, 95% CI 0.57 to 0.80) and prokinetic's (2 trials, RR 0.53, 95% CI 0.32 to 0.87). In treatment of ENRD, RR for heartburn remission for PPI versus placebo was 0.68 (4 trials, 95% CI 0.53 to 0.88) and for H2RA versus placebo was 0.84 (2 trials, 95% CI 0.74 to 0.95). The RR for PPI versus H2RA was 0.69 (2 trials, 95% CI 0.39 to 1.20) and versus prokinetic 0.72 (1 trial, 95% CI 0.56 to 0.92). The findings in this review suggest that antisecretory drugs are effective in the empirical treatment of complaints likely to originate from GORD and in treatment of ENRD and furthermore that PPIs are superior to H2RAs in empirical treatment of typical GORD symptoms.

Heartburn affects 25% of the adult population on a monthly basis and represents the core symptom of gastro-oesophageal reflux disease (GORD). Treatment is readily available and puts a large demand on healthcare budgets. A majority of GORD patients show no endoscopic abnormalities and in daily practice most patients are treated empirically. Summarise, quantify and compare the efficacy of the short-term use of proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and prokinetics in adults with GORD and endoscopy negative reflux disease (ENRD). We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2003), MEDLINE (January 1966 to December 2003), EMBASE (January 1988 to December 2003). Randomised controlled trials focussing on symptomatic outcome after short-term treatment for GORD using proton pump inhibitors, H2-receptor antagonists or prokinetic agents. Participants had to be classifiable in the empirical treatment group (no endoscopy used in treatment allocation) or in the endoscopy negative reflux disease group (no endoscopic signs of erosive oesophagitis). Two reviewers independently assessed trial quality and extracted data. Twenty-seven trials (8402 participants) were included: thirteen in the empirical treatment group, ten in the ENRD group and four in both. In empirical treatment of GORD the relative risk (RR) for heartburn remission in placebo-controlled trials for PPI was 0.37 (two trials, 95% confidence interval (CI) 0.32 to 0.44), for H2RAs 0.77 (two trials, 95% CI 0.60 to 0.99) and for prokinetics 0.86 (one trial, 95% CI 0.73 to 1.01). In a direct comparison PPIs were significantly (p < 0.05) more effective than H2RAs (five trials, RR 0.69, 95% CI 0.61 to 0.77) and prokinetics (two trials, RR 0.53, 95% CI 0.32 to 0.87). In treatment of ENRD, RR for heartburn remission for PPI versus placebo was 0.68 (six trials, 95% CI 0.59 to 0.78) and for H2RA versus placebo was 0.84 (two trials, 95% CI 0.74 to 0.95). The RR for PPI versus H2RA was 0.74 (three trials, 95% CI 0.53 to 1.03) and for PPI versus prokinetic 0.72 (one trial, 95% CI 0.56 to 0.92). The findings in this review suggest that antisecretory drugs are effective in the empirical treatment of complaints likely to originate from GORD and in treatment of ENRD and furthermore that PPIs are superior to H2RAs in empirical treatment of typical GORD symptoms.

PGI35 - ASSESSMENT OF ANTISECRETORY DRUGS CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

Ebrotidine is a new H2 receptor antagonist that potentiates the gastric mucosal barrier. To compare ebrotidine with other anti-secretory drugs in the prevention and healing of indomethacin-induced gastric lesions. Three different models of indomethacin-induced gastric lesions were used. (1) Fasted rat model: indomethacin was intra-gastrically administered in rats pre-treated with different doses of the anti-secretory drugs. (2) Re-fed rat model: rats orally treated with different doses of anti-secretory drugs had free access to chow pellets and were then treated with parenteral indomethacin. (3) Healing model: either oral or parenteral anti-secretory drugs were given after indomethacin administration. Computer-assisted analysis of the area of damage was expressed as ulcer index. Gastric secretion was evaluated in the pylorus-ligated rat model. Inhibition of acid secretion was in the order omeprazole > ebrotidine = ranitidine. Ebrotidine at the highest dose used (100 mg/kg) and omeprazole, but not ranitidine, significantly prevented indomethacin-induced corpus (fasted rat) and antrum (re-fed rat) gastric lesions. In the ulcer healing model, oral administration of omeprazole and both ranitidine and ebrotidine at the highest dose used improved the ulcer index. The parenteral administration of these drugs had a lesser effect than the oral route and was in the order ebrotidine > omeprazole > ranitidine. Ebrotidine is effective in both the prevention and healing of indomethacin-induced experimental gastric lesions. In these models, the effect of ebrotidine is comparable to omeprazole and more effective than ranitidine.

At present, antisecretory drugs--foremost among them the proton pump inhibitors (PPIs)--represent a keystone in Helicobacter pylori eradication therapy. The present article shall first compare the role of PPIs as compared with histamine H2 receptor antagonists, both of them in the role of antibiotic-associated antisecretory therapy, and shall then address the contribution of each of the various PPIs that have been developed until the present time to the H. pylori eradication therapies. In summary, it may be concluded that PPIs are more effective overall than H2 receptor antagonists when the two groups of antisecretory drugs are given at the usual standard doses together with antibiotics with the intention of eradicating H. pylori infection. However, all PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) are equivalent when given together with two antibiotics to cure the infection.

Reducing the Gastrointestinal Risks of Low-Dose Aspirin